{
    "nct_id": "NCT03625505",
    "official_title": "A Multicenter, Open-Label Phase 1b Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Subjects With Relapsed/Refractory Acute Myeloid Leukemia",
    "inclusion_criteria": "* Should have an established, confirmed diagnosis of Acute Myeloid Leukemia (AML) by World Health Organization (2016).\n* Should have failed at least 1 line of prior therapy (defined as failure to respond to therapy, and/or progression during or after therapy).\n* Should have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.\n* Should have adequate hematologic, kidney and liver function as described in the protocol.\n* For participants enrolling into the Expansion Cohort only: a documented FMS-like Tyrosine Kinase (FLT3) mutation in bone marrow or peripheral blood, as described in the protocol.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Has a diagnosis of acute promyelocytic leukemia (APL) or BCR-ABL-positive leukemia.\n* Has a history of other malignancies within 2 years prior to study entry, with exceptions as described in the protocol.\n* Has active central nervous system leukemia.\n* Has a history of chronic New York Heart Association (NYHA) class IV heart failure.\n* Has a corrected QT interval of > 450 ms.\n* Has a chronic respiratory disease that requires continuous oxygen use.",
    "miscellaneous_criteria": ""
}